Alzheimer's disease (AD) is the most prevalent type of dementia. Pathological changes in
the AD brain include amyloid‐β (Aβ) plaques and neurofibrillary tangles (NFTs), as well as …

Previous studies have shown that metalloproteinases (MMPs) participate in the clearance of
amyloid-β (Aβ) in Alzheimer's disease (AD); MMP2 and MMP3 cleave soluble Aβ, and both …

Matrix metalloproteinases (MMPs) and their natural tissue inhibitors (TIMPs) are involved in
cell signaling processes and the release of extracellular matrix (ECM) and non-ECM …

Matrix metalloproteinases (MMPs), a family of extracellular soluble or membrane bound
endopeptidases, are implicated in many physiological and pathophysiological functions …

A growing amount of evidence indicates that matrix metalloproteinases (MMPs) may play an
important role in the pathogenesis of Alzheimer's disease (AD). Stromelysin-1 (MMP-3) …

Pathological changes in the Alzheimer's disease (AD) brain include amyoid-β (Aβ) plaques,
and neurofibrillary tangles, as well as neuronal death and synaptic loss. Matrix …

Background: Deposition of amyloid β in senile plaques and in cerebral blood vessels is one
hallmark of the pathogenesis of Alzheimer's disease (AD). The ability of several matrix …

Matrix metalloproteinases (MMPs) are a group of proteinases that degrade components of
the extracellular matrix (ECM). There is increasing evidence for a link between the activation …

Background: A growing body of evidence shows the involvement of matrix
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in neurodegeneration …

Matrix metalloproteinases (MMPs)‐2,‐3 and‐9 are up‐regulated in several cell types on
exposure to amyloid β peptide (Aβ) and have Aβ‐degrading activity in vitro. The aims of this …